Targeting Siglec-10 with monoclonal antibodies effectively blocks this negative regulatory network, leading to a remarkable elevation in IFN-γ and IL-2 secretion, and synergistically enhancing CD8+ T cell anti-tumor cytotoxicity (100). Here, CD8A is linked to neoplasm.